share_log

Earnings Call Summary | NovaBay Pharmaceuticals(NBY.US) Q4 2023 Earnings Conference

Futu News ·  Mar 27 07:25  · Conference Call

The following is a summary of the NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • NovaBay reported a total Q4 2023 sales net of $3.7 million, marking a 2% increase from the previous year.

  • The gross margin on net product revenue for the quarter was 49%, slightly higher than the 48% of Q4 2022.

  • The company's net loss for Q4 2023 amounted to $9.2 million, or $1.33 per share.

  • For the whole of 2023, total sales net were $14.7 million, and cash and cash equivalents stood at $3.1 million at year end.

Business Progress:

  • NovaBay sold its skincare business DERMAdoctor, choosing to focus solely on its core eye care business.

  • The company saw a significant rise in subscription-based unit sales of Avenova Spray.

  • Launched two promotional programs for Avenova branded products, and extended its reach via a new co-marketing agreement with Eyenovia for the distribution of FDA-approved ophthalmic steroid, Clobetasol.

More details: NovaBay Pharmaceuticals IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment